Skip to main content
. 2019 Nov 12;8(22):e012655. doi: 10.1161/JAHA.119.012655

Figure 2.

Figure 2

Dose modification of renin–angiotensin–aldosterone system inhibitor prescriptions ending within 7 days of a serum potassium (K+) measurement, stratified by serum K+ threshold for CKD patients (A) and HF patients (B). Percentages of prescriptions that were maintained or up‐titrated are not shown; prescription numbers include all prescriptions, regardless of dose. The percentage of down‐titrated or discontinued prescriptions is shown on the bars, alongside the 95% CI (in brackets).